Gut Liver.  2015 Jul;9(4):516-524. 10.5009/gnl14162.

Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon alpha Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection

• Ali FT
• Ali MA
• Elgizawy M
• Elsawy AM

• KMID: 2160636
• DOI: http://doi.org/10.5009/gnl14162

Abstract

BACKGROUND/AIMS
The T-helper 1 (TH1) immune reaction is essential for the eradication of hepatitis C virus (HCV) during pegylated interferon alpha (PEG-IFN-alpha)- and ribavirin (RBV)-based therapy in chronic HCV patients. Secreted phosphoprotein 1 (SPP1) was shown to be a crucial cytokine for the initiation of a TH1 immune response. We aimed to investigate whether SPP1 single nucleotide polymorphisms (SNPs) may influence sustained virological response (SVR) rates.
METHODS
Two SNPs in the promoter region of SPP1 at the -443 C>T and -1748 G>A loci were genotyped in 100 patients with chronic HCV genotype 4 infection using a TaqMan SNP genotyping assay.
RESULTS
Sixty-seven patients achieved a SVR, and 33 patients showed no SVR. Patients carrying the T/T genotype at the -443 locus showed a significantly higher SVR rate than those carrying the C/T or C/C genotype (83.67% vs 50.98%, p<0.001). At the -1748 locus, the SVR rate was significantly higher in patients with the G/G genotype than in those with the A/A genotype (88.89% vs 52.63%, p=0.028) and in patients with the G/A genotype than in those with the A/A genotype (85.29% vs 52.63%, p=0.001).
CONCLUSIONS
SPP1 SNPs at -443 C>T and -1748 G>A loci may be useful markers for predicting the response to PEG-IFN-alpha-2b plus RBV therapy in Egyptian patients with chronic HCV genotype 4 infection.

Keyword

Chronic hepatitis C; Interferons; Response; Secreted phosphoprotein 1; Single nucleotide polymorphisms

MeSH Terms

Adult
Antiviral Agents/*therapeutic use
Biomarkers/blood
Drug Therapy, Combination
Egypt
Female
Genotype
Hepacivirus/drug effects/genetics
Hepatitis C, Chronic/*drug therapy/virology
Humans
Interferon-alpha/*therapeutic use
Male
Middle Aged
Osteopontin/*genetics
Polyethylene Glycols/*therapeutic use
Polymorphism, Single Nucleotide/genetics
Predictive Value of Tests
*Promoter Regions, Genetic
Recombinant Proteins/therapeutic use
Ribavirin/*therapeutic use
Treatment Outcome
Antiviral Agents
Biomarkers
Interferon-alpha
Osteopontin
Polyethylene Glycols
Recombinant Proteins
Ribavirin